TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23123915

Group type: EXPERIMENTAL
Intervention: Local laboratory measurements
Number of subjects: 0

Group type: COMPARATOR
Intervention: Central laboratory measurements
Number of subjects: 0
Study: 21550959

Group type: EXPERIMENTAL
Intervention: Insulin lispro mix 75/25
Number of subjects: 0

Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metformin/thiazolidinedione
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metformin/sulfonylurea/thiazolidinedione
Number of subjects: 0
Study: 18499631

Group type: EXPERIMENTAL
Intervention: Nerve stimulation (group NS)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Ultrasound guidance (group US)
Number of subjects: 80
Study: 16541243

Group type: EXPERIMENTAL
Intervention: 50 mg caffeine
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: 150 mg caffeine
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: 450 mg caffeine
Number of subjects: 102

Group type: COMPARATOR
Intervention: 0 mg caffeine (control)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: All caffeine doses (50, 150, 450 mg)
Number of subjects: 102
Study: 12704403

Group type: EXPERIMENTAL
Intervention: Orlistat 120 mg three times daily
Number of subjects: 696

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 696
Study: 10741634

Group type: EXPERIMENTAL
Intervention: Aspirin 325 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 9283061

Group type: EXPERIMENTAL
Intervention: Cuff size 13 x 23 cm
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Cuff size 13 x 36 cm
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Cuff size 16 x 23 cm
Number of subjects: 130
Study: 8396784

Group type: EXPERIMENTAL
Intervention: Spiradoline (0.0, 0.8, 1.6, and 3.2 micrograms/kg)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Spiradoline (1.6 micrograms/kg)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 3793549

Group type: EXPERIMENTAL
Intervention: 60 mg/m2 of doxorubicin every 3 weeks for eight courses
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Radiation therapy (optional)
Number of subjects: 225

Group type: COMPARATOR
Intervention: No radiation therapy
Number of subjects: 225
Study: 29684633

Group type: EXPERIMENTAL
Intervention: Carrageenan gel
Number of subjects: 280

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 280
Study: 29373432

Group type: EXPERIMENTAL
Intervention: Sprint Interval Training (SIT)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Endurance Training (ET)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: SIT and ET
Number of subjects: 15
Study: 26522923

Group type: EXPERIMENTAL
Intervention: Pulmonary Rehabilitation plus hyperproteic oral nutritional supplement enriched with HMB (PRONS)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Pulmonary Rehabilitation (PR)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups (PR and PRONS)
Number of subjects: 30
Study: 24439972

Group type: EXPERIMENTAL
Intervention: Triple Pill (initially strength 1-telmisartan 20 mg, amlodipine 2.5 mg, hydrochlorothiazide 6.25 mg, with the option of subsequent titration to strength 2-telmisartan 40 mg, amlodipine 5 mg, hydrochlorothiazide 12.5 mg)
Number of subjects: 700

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 700
Study: 22839453

Group type: EXPERIMENTAL
Intervention: Negative Pressure Wound Therapy (NPWT)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 12
Study: 20212299

Group type: EXPERIMENTAL
Intervention: CRP assistance
Number of subjects: 258

Group type: COMPARATOR
Intervention: Routine care (control)
Number of subjects: 258
Study: 18558915

Group type: EXPERIMENTAL
Intervention: Keeping the blues away (KBA) program
Number of subjects: 110

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 110
Study: 15999098

Group type: EXPERIMENTAL
Intervention: Fixed-dose rate gemcitabine
Number of subjects: 76
Study: 12453952

Group type: EXPERIMENTAL
Intervention: 10 mg glipizide (30 min premeal)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 120 mg nateglinide (15 min premeal)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 10 mg glipizide plus 120 mg nateglinide (30 and 15 min premeal, respectively)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (30 and 15 min premeal)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Nateglinide
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Glipizide
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Glipizide and Nateglinide
Number of subjects: 20
Study: 10353432

Group type: EXPERIMENTAL
Intervention: Venlafaxine 75 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Venlafaxine 150 mg
Number of subjects: 15

Group type: COMPARATOR
Intervention: Paroxetine 20 mg
Number of subjects: 15

Group type: COMPARATOR
Intervention: Desipramine 100 mg
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 8942420

Group type: EXPERIMENTAL
Intervention: Prepared meal plan
Number of subjects: 77

Group type: COMPARATOR
Intervention: Self-selected diet
Number of subjects: 77
Study: 9768208

Group type: EXPERIMENTAL
Intervention: Heberbiovac HB vaccine
Number of subjects: 106

Group type: COMPARATOR
Intervention: Engerix-B vaccine (control)
Number of subjects: 106
Study: 6383225

Group type: EXPERIMENTAL
Intervention: tranexamic acid
Number of subjects: 100

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 100
Study: 30666097

Group type: EXPERIMENTAL
Intervention: Meeting Centres Support Programme (MCSP)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 47
Study: 30080248

Group type: EXPERIMENTAL
Intervention: Home care management for PPROM
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: PPROM occurring before 26 weeks
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Non-cephalic fetal presentation
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Oligoamnios
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Combination of unfavorable criteria
Number of subjects: 187
Study: 27084855

Group type: EXPERIMENTAL
Intervention: Oral amoxicillin 1 gm, 1 hour preoperatively and 2 gm for 2 days postoperatively (Test group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: No antibiotics (Control group)
Number of subjects: 40
Study: 24799054

Group type: EXPERIMENTAL
Intervention: trastuzumab (4 mg/kg), gemcitabine (1000 mg/m(2)), docetaxel (50 mg/m(2))
Number of subjects: 65
Study: 23210420

Group type: EXPERIMENTAL
Intervention: 500 ppm F mouthwash
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 225 ppm F mouthwash
Number of subjects: 30

Group type: COMPARATOR
Intervention: 0 ppm F mouthwash
Number of subjects: 30
Study: 20451214

Group type: EXPERIMENTAL
Intervention: Mid-band spatial frequency bias in adults and 9- and 10-year-olds for upright faces
Number of subjects: 2

Group type: COMPARATOR
Intervention: Processing of upright and inverted faces in 7- and 8-year-olds
Number of subjects: 2
Study: 18758336

Group type: EXPERIMENTAL
Intervention: Class that used video demonstration and group teaching by a lactation consultant
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: New mothers' support group with one-on-one teaching prenatally and weekly meetings postpartum, taught by a lactation consultant and a pediatrician
Number of subjects: 194

Group type: COMPARATOR
Intervention: Control group educated at prenatal visits only
Number of subjects: 194
Study: 15768008

Group type: EXPERIMENTAL
Intervention: Vascular Quality of Life (VascuQol)
Number of subjects: 450

Group type: COMPARATOR
Intervention: Short Form 36 (SF‐36)
Number of subjects: 450

Group type: COMPARATOR
Intervention: European Quality of Life 5D (EuroQol‐5D)
Number of subjects: 450
Study: 11788218

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 2431

Group type: COMPARATOR
Intervention: Coronary artery bypass graft surgery (CABG)
Number of subjects: 2431

Group type: COMPARATOR
Intervention: Physician-directed registry (CABG)
Number of subjects: 2431

Group type: EXPERIMENTAL
Intervention: Physician-directed registry (PCI)
Number of subjects: 2431

Group type: EXPERIMENTAL
Intervention: Patient-choice registry (PCI)
Number of subjects: 2431

Group type: COMPARATOR
Intervention: Patient-choice registry (CABG)
Number of subjects: 2431
Study: 10627057

Group type: EXPERIMENTAL
Intervention: High-energy evening meal (11.91 +/‐ 0.86 MJ)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Average evening meal (5.74 +/‐ 0.88 MJ)
Number of subjects: 7

Group type: COMPARATOR
Intervention: 10-hour fast (no evening meal)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: All meal conditions (high-energy, average, and fast)
Number of subjects: 7
Study: 7806146

Group type: EXPERIMENTAL
Intervention: Octreotide (200 micrograms subcutaneously)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 2009800

Group type: EXPERIMENTAL
Intervention: PGE1
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 7384524

Group type: EXPERIMENTAL
Intervention: Ceruletide (0.3 microgram/kg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 30
Study: 30849076

Group type: EXPERIMENTAL
Intervention: Closed-loop insulin delivery
Number of subjects: 15

Group type: COMPARATOR
Intervention: Open-loop insulin delivery
Number of subjects: 15
Study: 26096071

Group type: EXPERIMENTAL
Intervention: Direct Anterior Approach (DAA)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Posterior Approach (PA)
Number of subjects: 51
Study: 25685075

Group type: EXPERIMENTAL
Intervention: Practice Facilitation (PF) intervention
Number of subjects: 40
Study: 22814329

Group type: EXPERIMENTAL
Intervention: Intravenous amphotericin B lipid complex (ABLC) 7.5 mg/kg weekly
Number of subjects: 40

Group type: COMPARATOR
Intervention: Oral posaconazole 200 mg three times per day
Number of subjects: 40
Study: 20061280

Group type: EXPERIMENTAL
Intervention: Computerized order set (CPOE)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 179
Study: 17983400

Group type: EXPERIMENTAL
Intervention: Six cycles of cytoxan, adriamycin and 5‐flurouricil (5‐FU)
Number of subjects: 464

Group type: COMPARATOR
Intervention: 16‐week regimen (weekly therapy with cytoxan, adriamycin, vincristine, methotrexate, and 5‐FU)
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: HRQOL score as a time‐dependent covariate
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: Nausea
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: Neurosensory toxicity
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: Hair loss
Number of subjects: 464
Study: 15727949

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) alone
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) plus Testosterone (T)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Testosterone (T) alone
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Testosterone (T) plus Growth Hormone (GH)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Combined treatments (GH and T)
Number of subjects: 12
Study: 12402373

Group type: EXPERIMENTAL
Intervention: 2 ml saline instillation
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 5 ml saline instillation
Number of subjects: 16

Group type: COMPARATOR
Intervention: 0 ml saline instillation (no saline)
Number of subjects: 16
Study: 9931783

Group type: EXPERIMENTAL
Intervention: Subtotal retroperitoneoscopic adrenal gland resection
Number of subjects: 24

Group type: COMPARATOR
Intervention: Complete adrenalectomy
Number of subjects: 24
Study: 8074058

Group type: EXPERIMENTAL
Intervention: Diluted meal (2671 kJ/L, 950 mL)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Concentrated meal (7452 kJ/L, 350 mL)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Both meals (diluted and concentrated)
Number of subjects: 9
Study: 2524360

Group type: EXPERIMENTAL
Intervention: Marvelon
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Microgynon 30
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Triquilar
Number of subjects: 0
Study: 30541475

Group type: EXPERIMENTAL
Intervention: Primary endpoint (PEP)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Secondary endpoint (SEP)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Total SEPs absent from registry and protocol
Number of subjects: 71
Study: 27582078

Group type: EXPERIMENTAL
Intervention: FOLFIRI + Sunitinib (SUN)
Number of subjects: 91

Group type: COMPARATOR
Intervention: FOLFIRI + Placebo (PL)
Number of subjects: 91
Study: 25641731

Group type: EXPERIMENTAL
Intervention: Ascorbic acid (500 mg)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Aspirin (600 mg)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Simultaneous dosage of ascorbic acid and aspirin
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 23732903

Group type: EXPERIMENTAL
Intervention: Pentavalent rotavirus vaccine RV5 (RotaTeq™), 3-dose regimen
Number of subjects: 0
Study: 20007736

Group type: EXPERIMENTAL
Intervention: Propofol (PROP)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Dexmedetomidine (DEX)
Number of subjects: 25
Study: 19025033

Group type: EXPERIMENTAL
Intervention: Adaptive training with identical stimuli
Number of subjects: 12

Group type: COMPARATOR
Intervention: Fixed training with identical stimuli
Number of subjects: 12
Study: 16882163

Group type: EXPERIMENTAL
Intervention: Coal tar (n = 13)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: All‐trans retinoic acid (atRA) (n = 14)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Clobetasol 17‐propionate (n = 10)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Vehicle control (white soft paraffin)
Number of subjects: 30
Study: 12928710

Group type: EXPERIMENTAL
Intervention: Prostaglandin E(1) injection before CTAP
Number of subjects: 30

Group type: COMPARATOR
Intervention: No prostaglandin E(1) injection (group A)
Number of subjects: 30
Study: 11211541

Group type: EXPERIMENTAL
Intervention: Monthly structured interventions for six months (Group 1, n = 42)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (Group 2, n = 38)
Number of subjects: 80
Study: 8801153

Group type: EXPERIMENTAL
Intervention: Burch colposuspension
Number of subjects: 81

Group type: COMPARATOR
Intervention: Anterior colporrhaphy
Number of subjects: 81
Study: 1519364

Group type: EXPERIMENTAL
Intervention: Autologous blood transfusions (predeposition of 2 units)
Number of subjects: 310

Group type: COMPARATOR
Intervention: Homologous blood transfusions (control)
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Autologous blood transfusions
Number of subjects: 310
Study: 6829481

Group type: EXPERIMENTAL
Intervention: Saturated fats (sat)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Monounsaturated fats (mono)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Omega-6 polyunsaturated fats (poly)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Cholesterol-free formula diet
Number of subjects: 12
Study: 30696677

Group type: EXPERIMENTAL
Intervention: Distraction-screw group
Number of subjects: 70

Group type: COMPARATOR
Intervention: Screw-distraction group
Number of subjects: 70
Study: 29768348

Group type: EXPERIMENTAL
Intervention: Deflection flexible visual gastric tube
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional method
Number of subjects: 20
Study: 27442715

Group type: EXPERIMENTAL
Intervention: Donepezil (10 mg)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 24554104

Group type: EXPERIMENTAL
Intervention: Autologous haematopoietic stem cell transplantation (HSCT)
Number of subjects: 48
Study: 22901308

Group type: EXPERIMENTAL
Intervention: SAMe 1600 mg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: SAMe 800 mg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 20003969

Group type: EXPERIMENTAL
Intervention: Needle-knife sphincterotomy (NKS)
Number of subjects: 732

Group type: COMPARATOR
Intervention: No NKS (Control)
Number of subjects: 732

Group type: EXPERIMENTAL
Intervention: NKS
Number of subjects: 732

Group type: EXPERIMENTAL
Intervention: Attempts at cannulating the papilla
Number of subjects: 732
Study: 17639099

Group type: EXPERIMENTAL
Intervention: Radial approach for PCI using abciximab
Number of subjects: 114

Group type: COMPARATOR
Intervention: Femoral approach for PCI using abciximab
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Both approaches
Number of subjects: 114
Study: 15887009

Group type: EXPERIMENTAL
Intervention: Valdecoxib 20 mg single dose on day 1 and 20 mg twice daily on days 4-7, followed by a single morning dose on day 8.
Number of subjects: 25
Study: 12492725

Group type: EXPERIMENTAL
Intervention: Desloratadine, 5 mg once daily
Number of subjects: 190

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 190
Study: 9799756

Group type: EXPERIMENTAL
Intervention: Cyclic or continuous hormone replacement therapy (HRT) with an estrogen analog (tibolone)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bisphosphonate (ibandronate)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Serum CrossLaps One Step ELISA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Urine CrossLaps ELISA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Serum CrossLaps One Step ELISA vs Urine CrossLaps ELISA
Number of subjects: 0
Study: 8557555

Group type: EXPERIMENTAL
Intervention: ICU length of stay
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Total hospital length of stay
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Functional status at 6-month follow-up
Number of subjects: 45
Study: 2199209

Group type: EXPERIMENTAL
Intervention: Inhaled frusemide (approximately 28 mg)
Number of subjects: 12
Study: 189724

Group type: EXPERIMENTAL
Intervention: Fluphenazine hydrochloride orally
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluphenazine decanoate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31502640

Group type: EXPERIMENTAL
Intervention: Deep Dry Needling (DDN)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Ischemic Compression (ICT)
Number of subjects: 34
Study: 29806557

Group type: EXPERIMENTAL
Intervention: Individuals with hypertension (n=219)
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Obese individuals (BMI ≥30 kg/m2)
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Individuals with hypertension
Number of subjects: 330
Study: 28588021

Group type: EXPERIMENTAL
Intervention: Isosorbide mononitrate
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study: 25881936

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day
Number of subjects: 9572

Group type: COMPARATOR
Intervention: Atorvastatin 10 mg/day
Number of subjects: 9572

Group type: EXPERIMENTAL
Intervention: LDL-C variability (by ASV)
Number of subjects: 9572
Study: 23689947

Group type: EXPERIMENTAL
Intervention: GHRH (tesamorelin, 1 mg/d)
Number of subjects: 30
Study: 21926261

Group type: EXPERIMENTAL
Intervention: Valsartan for 1 year
Number of subjects: 340
Study: 18483726

Group type: EXPERIMENTAL
Intervention: Donepezil (5 mg/day after an induction period of 3 mg/day for 2 weeks)
Number of subjects: 15
Study: 15969845

Group type: EXPERIMENTAL
Intervention: Cognitive intervention study
Number of subjects: 0
Study: 11951094

Group type: EXPERIMENTAL
Intervention: Cilostazol 100 mg twice daily
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: Cilostazol 50 mg twice daily
Number of subjects: 394

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 394
Study: 9794344

Group type: EXPERIMENTAL
Intervention: QoL collected before randomization
Number of subjects: 200

Group type: COMPARATOR
Intervention: QoL collected after randomization
Number of subjects: 200
Study: 7885426

Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol (800 micrograms)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Oral misoprostol (800 micrograms)
Number of subjects: 270
Study: 2198211

Group type: EXPERIMENTAL
Intervention: 750 mg sultamicillin (STM) b.i.d.
Number of subjects: 132

Group type: COMPARATOR
Intervention: 625 mg amoxicillin/clavulanate (AMX/CLA) t.i.d.
Number of subjects: 132
Study: 333869

Group type: EXPERIMENTAL
Intervention: Calcium clofibrate (2 g)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cholestyramine (12 g)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of calcium clofibrate and calcium carbonate (2 + 2 g)
Number of subjects: 0
Study: 31600031

Group type: EXPERIMENTAL
Intervention: Electric heating pad (40°C) applied for 10 minutes before IV insertion
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group (no heating pad)
Number of subjects: 84
Study: 31129484

Group type: EXPERIMENTAL
Intervention: Dosed Exercise Intervention (DEI)
Number of subjects: 302

Group type: COMPARATOR
Intervention: Health Education Intervention (HEI)
Number of subjects: 302
Study: 28012035

Group type: EXPERIMENTAL
Intervention: Sorafenib (4-week treatment prior to surgery)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (4-week treatment prior to surgery)
Number of subjects: 20
Study: 25359924

Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN-α) antiviral therapy
Number of subjects: 91
Study: 24018224

Group type: EXPERIMENTAL
Intervention: Mindfulness-based relapse prevention (MBRP)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Relapse prevention (RP)
Number of subjects: 70
Study: 21813054

Group type: EXPERIMENTAL
Intervention: Fatigue Visual Analogue Scale (VAS)
Number of subjects: 1121
Study: 19786646

Group type: EXPERIMENTAL
Intervention: Sesame supplementation (25 g/d of sesame, approximately 50 mg/d of sesame lignan)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Isocaloric matched control
Number of subjects: 33
Study: 16764130

Group type: EXPERIMENTAL
Intervention: WMTA
Number of subjects: 48

Group type: COMPARATOR
Intervention: CH
Number of subjects: 48
Study: 15182126

Group type: EXPERIMENTAL
Intervention: Propranolol (0.05 mg/kg)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 13